In terms of feasibility, in our hands, semiquantitative scoring of CAD and CPS1 immunoreactivity was adapted in analogy to the scoring of hormone receptor and HER2neu expression, which is part of routine histopathological diagnostics of breast cancer. This evidence concerns the gene NR4A1 and breast cancer.